Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD30 + status confers therapeutic sensitivity to Brentuximab Vedotin in patients with Hodgkin Lymphoma.
The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ Hodgkin lymphoma (HL) at increased risk of relapase or progression following autologous stemc ell transplant (ASCT).
This statement is based on a regulatory approval from the European Medicines Agency:
ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).